NL-OMON53625尚未招募不适用
The effects of reduced dose alemtuzumab for severe kidney transplant rejection - ROSETTE
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •In order to be eligible to participate in this study, a subject must meet all
- •of the following criteria:
- •- 18 years or older
- •- Treatment for severe or glucocorticoid-resistant kidney transplant rejection
- •with alemtuzumab.
排除标准
- •A potential subject who meets any of the following criteria will be excluded
- •from participation in this study:
- •- Treatment with a different lymphocyte depleting agent (e.g. rATG) prior to
- •treatment with alemtuzumab for the same rejection episode.
- •- Recipients who have T cell counts below 200 × 106/L before the start of
- •therapy (for instance, because of lymphocyte depleting induction therapies).
- •- Inability to provide written informed consent
研究者
相似试验
已完成
不适用
Alemtuzumab as remission induction for adult patients with acute lymphoblastic leukemia in relapse: a randomized phase II studyAcute lymphoblastic leukemia (ALL)LeukemiaCancerISRCTN86445183Dutch Haemato-oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON)120
进行中（未招募）
不适用
Therapy with Alemtuzumab (Mabcampath) in patients with acute Lymphoblastic leukemia either refractoy or in relapse. Phase II, multicentric, not randomized study.EUCTR2004-001739-53-ITG.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
已完成
不适用
Effect of adalimumab dose escalation in patients with Crohn's diseases diseaseCrohn's diseaseJPRN-UMIN000023719Shiga University of Medical Science
尚未招募
2 期
The effect of Adalimumab in the treatment of patients with chronic schizophreniaSchizophrenia.SchizophreniaIRCT20090117001556N126Tehran University of Medical Sciences50
已完成
2 期
Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune CytopeniasAnemia, Hemolytic, AutoimmuneIdiopathic Thrombocytopenic PurpuraNCT00749112Hospital Universitario Dr. Jose E. Gonzalez19